Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 October 2020 : Clinical Research  

Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients

Naro Ohashi1ABCDEF*, Taro Aoki1BCE, Takashi Matsuyama1BCE, Sayaka Ishigaki2BCE, Shinsuke Isobe1BCE, Tomoyuki Fujikura1A, Takuya Hashimoto3ABDE, Daisuke Tsuriya3ABDE, Hiroshi Morita3ABDE, Akihiko Kato2AD, Hideo Yasuda1ACDE

DOI: 10.12659/MSM.926086

Med Sci Monit 2020; 26:e926086

Table 4 Relationships between the percentage changes in serum uric acid levels and clinical parameters from baseline to 6 months after sodium-glucose cotransporter-2 inhibitor administration.

RP-value
Body weight (kg)0.190.40
Body mass index (kg/m)0.190.40
Systolic blood pressure (mmHg)−0.190.41
Diastolic blood pressure (mmHg)−0.0820.72
Heart rate (/min)−0.0690.83
Hemoglobin (g/dL)−0.350.090
Blood urea nitrogen (mg/dL)0.220.30
Cr (mg/dL)0.470.020
eGFR (mL/min/1.73 m)−0.470.022
Hemoglobin A1c (%)0.210.33
Low-density lipoprotein cholesterol (mg/dL)0.0280.90
Triglyceride (mg/dL)0.0600.78
Log urinary albumin/Cr (mg/g)−0.210.35
Log urinary protein/Cr (g/g)0.140.56
Fractional excretion of glucose (%)−0.130.58
Fractional excretion of uric acid (%)0.140.58
eGFR – estimated glomerular filtration rate, Cr – creatinine.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750